NexaGen Pharmaceuticals develops breakthrough therapeutics targeting the most challenging diseases. Our proprietary platforms are transforming treatment paradigms in neuroscience, oncology, and rare diseases.
Our portfolio of approved treatments improving lives across multiple therapeutic areas.
Next-generation anxiolytic with rapid onset and minimal side effects. Over 2 million prescriptions since 2041 approval.
Nootropic therapy for age-related cognitive decline. Clinically proven to improve memory and focus in adults 55+.
Checkpoint inhibitor for advanced solid tumors. Breakthrough therapy designation for metastatic melanoma.
Gene therapy for hereditary cardiomyopathy. First approved cardiac gene therapy in North America.
Monoclonal antibody for severe osteoporosis. Once-yearly injection that rebuilds bone density.
Gene therapy for inherited retinal dystrophies. Restoring sight to patients with previously untreatable conditions.
Our state-of-the-art research campus in Metro City's Biotech Corridor houses over 800 scientists working on the therapies of tomorrow.
Our robust pipeline includes promising candidates across multiple therapeutic areas.
Help us develop the therapies that will define the future of medicine
View Career Opportunities